Pegenzileukin - Sanofi
Alternative Names: IBI-127; Non alpha IL-2 - Sanofi; Non alpha synthorin of IL-2 - Sanofi; SAR-444245; THOR-707Latest Information Update: 05 Nov 2023
At a glance
- Originator Synthorx
- Developer Merck Sharp & Dohme; Sanofi
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Interleukin 2 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II B-cell lymphoma; Gastrointestinal cancer; Hodgkin's disease; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Squamous cell cancer
- Phase I/II Solid tumours
Most Recent Events
- 25 Jul 2023 Sanofi withdraws phase-II trial in Squamous cell cancer (Combination therapy, Neoadjuvant therapy) in USA (IV) prior to enrolment due to principal investigator request (NCT05535023)
- 08 Jun 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 14 Apr 2023 Pharmacodynamics data from a phase I/II trial in Solid tumours at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)